X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

AMR101 – Omega-3-Based Treatment for Hypertriglyceridaemia, United Kingdom

Yuvraj_pawp by Yuvraj_pawp
6th September 2014
in Europe, Projects

Under development by Amarin Corporation, AMR101 is a partially synthetic omega-3 fatty acid-based drug. It contains the purest form of the active ingredient, ethyl ester of eicosapentaenoic acid (ethyl-EPA).

AMR101 is being developed for the treatment of hypertriglyceridaemia, which is a key cause for cardiovascular diseases. Phase III clinical trials were completed in April 2011; Amarin plans to submit a new drug application for AMR101 to the US Food and Drug Administration (FDA) in the third quarter of 2011.

Hypertriglyceridaemia – cause and effect

Hypertriglyceridaemia is described as a condition in which triglycerides (a type of fat found in the blood) are present in high levels in the body. Triglycerides are produced from food and are also manufactured by the liver.

Hypertriglyceridaemia is known to increase the risk of cardiovascular diseases and cause a range of lipid disorders such as dyslipidemia.

Hypertriglyceridaemia can intensify with age and is more prevalent in people who are overweight or obese. It can also be caused by uncontrolled diabetes mellitus and a sedentary lifestyle. If the cause of the disease is genetic then it is known as familial hypertriglyceridaemia.

In the US, it is estimated that about 27 million individuals have high triglyceride levels and are at risk of developing cardiovascular diseases. They are also at the risk of developing other metabolic disorders such as diabetes and obesity.

AMR101 – ultra pure ethyl-EPA

“Hypertrigly – ceridaemia is known to increase the risk of cardiovascular diseases.”

In clinical studies the active ingredient in AMR101, ethyl-EPA, has shown its effectiveness in lowering high triglyceride levels. Irrespective of the degree of severity, AMR101 is effective in reducing plasma triglycerides in hypertriglyceridaemia patients.

Studies have also shown the safety and efficacy of AMR101 on a number of other elements in the body such as cell membrane composition and regulation of glucose metabolism. It has also been shown to be effective as an anti-inflammatory mechanism.

AMR101 has also been tested for central nervous system disorders such as Huntington’s disease. A Marketing Authorization Application for the treatment of the disease is pending with the European Medicines Agency following positive results from Phase III clinical trials. AMR101 has also received Orphan Medicinal Product designation in the EU for the treatment of the disease.

Global clinical trials for AMR101

In January 2008, Amarin was granted regulatory approval to initiate Phase IIa trials with AMR101 for age-associated memory impairment. The randomised, double-blind, placebo-controlled trial was carried out in the UK and enrolled 96 patients. It was initiated following positive results from pre-clinical studies in memory and cognition. The drug met all the primary objectives of the trial.

In July 2008, Amarin began Phase III development of AMR101 for the treatment of hypertriglyceridaemia. The company launched two Phase III clinical studies, the MARINE and ANCHOR studies. In January 2010, the first patients for the two studies were enrolled by the company. The studies were conducted under a Special Protocol Agreement with the FDA. The agreement covered the design, endpoints and statistical analysis of the Phase III clinical studies.

The MARINE study was a placebo-controlled, randomised, double-blind trial that recruited 229 patients. The 12-week study was conducted in North and Central America, Europe, India and South Africa, and was designed to assess the safety and efficacy of AMR101 in patients with high triglyceride levels.

In November 2010, results of the MARINE study were announced, and the drug was confirmed to have met both the trial’s primary and secondary endpoints. The study also showed that there was statically no increase in low-density lipoprotein cholesterol (LDL-C) levels. The safety profile of AMR101 was also found to be similar to placebo.

The ANCHOR study was a placebo-controlled, randomised, double-blind trial that involved 702 patients. The 12-week study assessed the safety and efficacy of AMR101 in individuals with high triglyceride levels who were undergoing statin therapy. It was conducted across various centres in the US.

Results of the ANCHOR study, announced in April 2011, indicated that AMR101 is effective in statistically decreasing LDL-C levels. The drug met all of the trial’s primary and secondary endpoints.

Marketing commentary

It is estimated that the number of hypertriglyceridaemia and dyslipidaemia cases in the US is more than 100 million. The market for these treatments is estimated to be more than $25m and predominantly includes treatments by statin therapies.

“The active ingredient in AMR101, ethyl-EPA, has shown its effectiveness in lowering high triglyceride levels.”

The non-statin market is growing steadily and represents a new approach towards treating such diseases. Instead of focusing on reducing low-density lipoprotein cholesterol, a key factor in causing dyslipidaemia, treatments are moving towards other factors such as regulation of high-density lipoprotein cholesterol and triglycerides.

If approved AMR101 will be the first omega-3 based drug in the market for treating both high triglycerides levels and mixed dyslipidaemia. At the moment Lovaza is the only omega-3 based drug approved in the market for the treatment of high triglycerides levels.

AMR101 will also be entitled to ten years of market exclusivity in the EU following its designation as an Orphan Medicinal Product. This considerably improves the drug’s prospects in the market for the treatment of Huntington’s disease.

Tags: Europe
Previous Post

Viropro cGMP Biomanufacturing Facility, Malaysia

Next Post

Signifor (Pasireotide) - Treatment for Cushing’s Disease, Germany

Related Posts

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
Europe

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

26th April 2021
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia
Europe

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

26th September 2020
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
Europe

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

21st September 2020
Europe

Pharmintech 2019: Big increase in International Participation Expected

18th November 2018
Europe

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

17th August 2018
Next Post

Signifor (Pasireotide) - Treatment for Cushing’s Disease, Germany

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In